Business UpdateJul 15, 2026, 07:46 AM
Profound Medical's TULSA Procedure Highlighted at Robotic Surgery Meeting
AI Summary
Profound Medical Corp. announced that its TULSA Procedure™ will be prominently featured in several presentations by leading physicians at the upcoming Society of Robotic Surgery (SRS) Annual Meeting. The presentations will cover various clinical outcomes and applications of the MRI-guided, AI-powered prostate ablation technology. Additionally, Profound was selected as one of eight companies to be spotlighted during the Society of Incisionless Surgery (SIS) plenary session, and its management will participate in an investor session at the conference.
Key Highlights
- Profound Medical's TULSA Procedure to be highlighted in multiple presentations at the Society of Robotic Surgery (SRS) Annual Meeting from July 23-26, 2026.
- Presentations will cover real-world outcomes, CAPTAIN trial safety, single-center efficacy, and salvage TULSA for recurrent prostate cancer.
- Dr. Xiaosong Meng and Dr. Victoria Y. Bird are among the leading physicians presenting TULSA outcomes.
- Profound Medical was selected as one of eight companies to be spotlighted during the Society of Incisionless Surgery (SIS) plenary session at SRS2026.
- Profound's management team will participate in an SRS Investor Session on July 22, 2026, moderated by Stifel and Wells Fargo analysts.
- TULSA-PRO is an MRI-guided, AI-powered, robotically-driven, and incisionless procedure for prostate ablation.
- The company also commercializes Sonalleve for pain palliation of bone metastases and gynecologic conditions.
Price Impact
More from PROF